Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;174(9):1460-7.
doi: 10.1001/jamainternmed.2014.3028.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

Grace L Lu-Yao  1 , Peter C Albertsen  2 , Dirk F Moore  3 , Weichung Shih  3 , Yong Lin  3 , Robert S DiPaola  4 , Siu-Long Yao  5
Affiliations

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

Grace L Lu-Yao et al. JAMA Intern Med. 2014 Sep.

Abstract

Importance: One in 6 American men will be diagnosed as having prostate cancer during their lifetime. Although there are no data to support the use of primary androgen-deprivation therapy (ADT) for early-stage prostate cancer, primary ADT has been widely used for localized prostate cancer, especially among older patients.

Objective: To determine the long-term survival impact of primary ADT in older men with localized (T1/T2) prostate cancer.

Design, setting, and participants: This was a population-based cohort study of 66,717 Medicare patients 66 years or older diagnosed from 1992 through 2009 who received no definitive local therapy within 180 days of prostate cancer diagnosis. The study was conducted in predefined US geographical areas covered by the Surveillance, Epidemiology, and End Results (SEER) Program. Instrumental variable analysis was used to assess the impact of primary ADT and control for potential biases associated with unmeasured confounding variables. The instrumental variable comprised combined health services areas with various usage rates of primary ADT. The analysis compared survival outcomes in the top tertile areas with those in the bottom tertile areas.

Main outcomes and measures: Prostate cancer-specific survival and overall survival.

Results: With a median follow-up of 110 months, primary ADT was not associated with improved 15-year overall or prostate cancer-specific survival following the diagnosis of localized prostate cancer. Among patients with moderately differentiated cancers, the 15-year overall survival was 20.0% in areas with high primary ADT use vs 20.8% in areas with low use (difference: 95% CI, -2.2% to 0.4%), and the 15-year prostate cancer survival was 90.6% in both high- and low-use areas (difference: 95% CI, -1.1% to 1.2%). Among patients with poorly differentiated cancers, the 15-year cancer-specific survival was 78.6% in high-use areas vs 78.5%, in low-use areas (difference: 95% CI, -1.8% to 2.4%), and the 15-year overall survival was 8.6% in high-use areas vs 9.2% in low-use areas (difference: 95% CI, -1.5% to 0.4%).

Conclusions and relevance: Primary ADT is not associated with improved long-term overall or disease-specific survival for men with localized prostate cancer. Primary ADT should be used only to palliate symptoms of disease or prevent imminent symptoms associated with disease progression.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: During the past 5 years, Dr Lu-Yao has received a consulting fee from the Merck Research Laboratory, Dr Shih has received clinical research funding from Myriad, and Dr Yao has been employed by Schering-Plough and Merck in the area of clinical cancer research.

Figures

Figure
Figure. Adjusted Prostate Cancer-Specific Survival and Overall Survival in High Use and Low Use of Health Service Areas (HSAs) by Cancer Grade
Results were adjusted for age, race, comorbidity status, cancer stage, zip code income, zip code education, urban area, marital status, year of diagnosis, state buy-in status. A, Prostate cancer-specific survival was similar in areas with high and low use of primary androgen deprivation therapy (ADT) (high use and low use, respectively) among men with moderately differentiated cancer and poorly differentiated cancer. B, Overall survival was similar in highland low-use areas among men with moderately differentiated cancer and poorly differentiated cancer.
See this image and copyright information in PMC

Comment in

References

    1. Cooperberg MR, Broering JM, Litwin MS, et al. CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol. 2004;171(4):1393–1401. - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. [Accessed January 30, 2013];Prostate Cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#prostate.
    1. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–1624. - PubMed
    1. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173–181. - PMC - PubMed
    1. Studer UE, Collette L, Whelan P, et al. EORTC Genitourinary Group. Using PSA to guide timing of androgen deprivation in patients with TO-4 NO-2 MO prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol. 2008;53(5):941–949. - PubMed

Publication types

MeSH terms

Substances